Newsletter · · Ashutosh Agarwal

Moderna and Merck Cancer Vaccine Data Sends Biotech Soaring - Weekly Pharma, Biotech and Life Sciences Podcast Recap - Week of August 23, 2026

Positive Phase 3 melanoma data from the Moderna and Merck personalized cancer vaccine drove Moderna up well over 100 percent and Merck to a record high, the dominant story across pharma and biotech podcasts for the week of August 16 to 23, 2026. This recap also covers falling GLP-1 prices and China supply, a mid-cap M and A wave, AI in drug discovery, and a new FDA nominee.

Weekly Pharma / Biotech / Life Sciences Podcast Recap

Week of August 23, 2026: Moderna and Merck Cancer Vaccine Data Sends Biotech Soaring

This was one of the busiest weeks for biotech podcasts in a while, and it had a clear main character: the cancer vaccine that Moderna and Merck are developing together. Positive late-stage trial results in melanoma (a serious skin cancer) sent Moderna's stock up well over 100% in a single day and pushed Merck to a record high, and the story spilled into nearly every markets-and-investing show. Around that headline, the obesity-drug (GLP-1) conversation kept rolling, mid-sized drug companies stayed on a buying spree, artificial intelligence in drug discovery got a fresh round of debate, and Washington served up a new FDA commissioner nominee. Below is the substance, in plain English, with the specific numbers and quotes as the guests said them.

(A quick glossary for terms that come up a lot: GLP-1 is the class of appetite-suppressing drugs behind Ozempic, Wegovy, Mounjaro and Zepbound. mRNA is the "instruction molecule" technology behind the COVID vaccines, now being aimed at cancer. Patent cliff means the point where a blockbuster drug loses patent protection and cheaper copies crush its sales. ADC (antibody-drug conjugate) is a targeted "guided missile" chemo. PFS/OS are progression-free survival / overall survival, the two big cancer trial yardsticks.)

1. Dominant Themes

Theme 1: The Moderna/Merck cancer vaccine was the story of the week

The single biggest event was Moderna and Merck reporting positive Phase 3 (final-stage) data for a personalized cancer vaccine used alongside Merck's blockbuster immunotherapy Keytruda, in patients whose melanoma had been surgically removed. On Squawk Pod, host Becky Quick laid out the market reaction in real time: Merck up about 7.75% (from a $333 billion company), and Moderna up 63% early, trading at $102 and worth "$38 to $40 billion now" versus roughly $25 billion before the news; later in the same interview she noted the stock was up 74%.

How it works, in the words of the two executives who ran the programs: Merck's research chief Dr. Dean Li described Keytruda as the drug that "unlocks the key to let the hound dogs out," while Moderna's vaccine gives the immune system "the scent, the signature" of a patient's own tumor. Moderna CEO Stephane Bancel stressed the treatment is genuinely one-of-a-kind per patient: "You will get a different drug if you're diagnosed with melanoma today and I'm diagnosed by the same doc… we're going to sequence all the letters of the DNA of your cancer cell," then an algorithm picks "34 mutations that we believe are the most important in your tumor," stitched into a single mRNA molecule (Squawk Pod). Crucially for the cost debate, Bancel pointed out this is not like CAR-T cell therapy: "we do not use your own cells to make the product… It's enzymes. It's a chemical process," which he argued can be made cheaper and faster. The companies pointedly did not release specific efficacy numbers, saving full data for a major oncology meeting this fall and a peer-reviewed journal, though Dr. Li cited the earlier Phase 2 as showing a "40 to 50%" reduction in the risk of recurrence, with most disease-free patients staying disease-free out to five years.

Analysts were more measured than the stock move. On CNBC's "Fast Money", Mizuho healthcare specialist Jared Holz explained the size of the pop was partly a "short squeeze": "50 million shares short to begin the day. You knew this was going to happen," but said the real significance is proof "that mRNA is a viable technology outside of respiratory diseases." Bloomberg Intelligence's Sam Fazeli struck a caution note, calling melanoma "the easiest step forward" and warning that broader use in other tumors is still unproven (Bloomberg Intelligence). Other shows added scale: about 100,000 Americans are diagnosed with melanoma a year with roughly 8,500 deaths, and Moderna was up around 250% at one point, with possible approval by 2027 (Limitless: An AI Podcast). Data in other tumor types (Moderna/Merck across several cancers) is expected in 2027, and hosts flagged BioNTech (running its own cancer-vaccine trials including bladder cancer) as a cheaper way to play the same theme (CNBC's "Fast Money"; Telltales).

Theme 2: GLP-1 prices are heading down, and China quietly controls the supply

The obesity-drug conversation shifted from "who has the best drug" to "how cheap can this get, and who actually makes it." On On The Pen GLP-1 News, host Dave Knapp highlighted that Hims & Hers CEO Andrew Dudum believes Zepbound's cash price could eventually fall to "$40 or $50 a month," driven by a wave of new competitors (Boehringer Ingelheim, Viking Therapeutics, Pfizer via its MetSera acquisition, and Amgen's MariTide) plus relentless competition between Eli Lilly and Novo Nordisk and the persistent compounding/"gray market." The more striking point was the supply chain: citing a Bloomberg report, the episode described Chinese pharmaceutical-services giant WuXi AppTech as having a "GLP-1 chokehold" and being "too big to ban," because most GLP-1 drugs, however you buy them, rely on peptide synthesis and manufacturing steps that trace back to China, even as Washington pushes for domestic supply independence.

On the demand side, the numbers guests threw around were large. DHUnplugged cited Lilly's tirzepatide generating $9.94 billion (Mounjaro, for diabetes) and $4.93 billion (Zepbound, for weight loss), and even blamed weak McDonald's sales partly on GLP-1s curbing fast-food appetite. Telltales reported Lilly's Q2 revenue at $23 billion, up 48%, an 11% beat, with full-year earnings guidance raised to $35.50–$36.50, plus a first European (UK) approval for its oral GLP-1 pill and up to $3.8 billion in vaccine-biotech acquisitions. A recurring practical caveat from clinicians: GLP-1s alone drive muscle loss, up to 35% of weight lost can be lean mass without support (Health Care Rounds), which is spawning a whole "GLP-1 companion" market of supplements and OTC products (Citeline Podcasts).

Theme 3: Mid-sized drug companies are the new buyers

A clear structural shift: small and mid-cap drug companies that have proven they can launch their own products are now doing large acquisitions themselves, rather than selling out to Big Pharma. On Citeline Podcasts, Scrip's Jessica Merrill reported "8 acquisitions by small- to mid-cap companies this year with upfront values of more than $1 billion in the first half of 2026… versus 3 in all of 2025," a big leap. Named deals: argenx buying Forte Biosciences for $2.2 billion (adding celiac disease and vitiligo programs), Jazz buying Actio for $820 million (rare epilepsy), plus deals from Insmed, Servier, Neurocrine, Alkermes and UCB. Merrill's thesis is that companies like argenx, whose myasthenia-gravis drug Vyvgart is "about to exceed $6 billion in sales this year," have reached profitability and want to "extend that trajectory… into the next decade" as independent players. Separately, on the markets side, guests noted Q2 was the busiest quarter this decade for biopharma M&A by value and floated speculation about an AstraZeneca–Bristol Myers combination (Squawk on the Street), and a Boston Scientific acquisition of Penumbra for roughly $14 billion came up as a medtech example (Random Musings From The Clinical Trials Guru).

Theme 4: AI in drug discovery, from prediction to invention

Several shows dug into whether AI is genuinely changing drug discovery. On The Big Unlock, Insilico Medicine founder Alex Zhavoronkov (the company is publicly traded in Hong Kong) said Insilico now has 32 development candidates, 8 in Phase 1, 3 in Phase 2 and 1 in Phase 3, and orchestrates over 1,200 tasks across the discovery pipeline. The recurring proof point across shows was Insilico's AI-designed lung-fibrosis drug reaching the clinic in about 18 months versus a traditional 4–6 years (Chat GPT Podcast). That same episode was careful to temper the hype: AI's biggest near-term value is better early screening to cut expensive late-stage failures, not lowering drug prices, and it's held back by biased, mostly-positive scientific data. Ron Alfa, CEO of NOETIK and a former AI lead at Recursion, framed drug discovery as "biology as a search problem," describing an AI agent that "zero-shot" discovered a first-in-class drug target from patient data (Once a Scientist). And Ginkgo Bioworks CEO Jason Kelly said GPT-5 designed 30,000 experiments a week and beat a Stanford protein-production benchmark by 40% in six rounds, arguing the industry's ~$80 billion annual pharma R&D lab spend is ripe for automation (Inside the ICE House).

Theme 5: Washington, a new FDA nominee and ongoing vaccine turmoil

President Trump nominated Dr. Heidi Overton to run the FDA. On Citeline Podcasts' Drug Fix, reporters described her as an MD (University of New Mexico) with a PhD from Johns Hopkins whose career has been "almost entirely in policy and politics," a White House fellow and America First Policy Institute alum, "really good at managing up." The flashpoint is vaccines: she appeared at Trump's childhood-vaccine executive-order event and urged states to adopt new recommendations "many doctors say are not supported by current science," and even Republican Senate Health Chair Bill Cassidy called her involvement "almost disqualifying." The episode noted the nomination landed while the Senate was in recess, read as an attempt to keep vaccine and abortion-pill (mifepristone) tensions out of the spotlight ahead of the midterms, on top of an FDA already hit by mass layoffs and senior departures. Meanwhile, the White House brought in Chris Klomp as a "guardrail" around HHS Secretary RFK Jr.'s vaccine agenda (Tradeoffs), and both Merck and GSK stated they have no intention of developing standalone MMR vaccines in response to the push to split the shot (Confessions of a Male Gynecologist).

Theme 6: A steady drumbeat of oncology and cell/gene therapy readouts

Away from the headlines, the oncology-education podcasts were dense with practice-changing data. Highlights: the FDA approved iberdomide (brand name Zenbexis; a protein-degrader pill) with daratumumab/dexamethasone for relapsed multiple myeloma, based on 41% MRD-negativity versus 21%, notably the first myeloma trial to use MRD and PFS as co-primary endpoints, though approval came on the MRD data alone (OncoPharm; Oncology Brothers). In gastric cancer, zanidatamab plus chemo improved progression-free survival by 4+ months and a zanidatamab-tislelizumab triplet improved overall survival by 7+ months versus the trastuzumab standard (Research To Practice). Oncologists repeatedly flagged daraxonrasib, an oral KRAS inhibitor, as the year's biggest news for the hard-to-treat KRAS-driven tumors, with dramatic survival extension in pancreatic cancer and approval expected within months (Becker's Healthcare; OncLive On Air). On the gene-therapy side, Capricor's cardiosphere therapy for Duchenne muscular dystrophy hit its limb-function endpoint but was rejected 9–3 by an FDA advisory committee for the heart-muscle indication, so the company is pursuing DMD limb function alone (BioCentury This Week).

2. Active Debates

Is the Moderna cancer vaccine a real franchise or a one-trial pop? Bulls point to genuine proof that mRNA works beyond respiratory disease and a pipeline of nine more tumor trials. Skeptics (Fazeli, Holz) counter that melanoma is the "easiest" tumor for immunotherapy, the huge move was amplified by short covering, full efficacy numbers haven't been shown, and manufacturing a truly individualized product at scale takes real "human capital" (CNBC's "Fast Money"; Bloomberg Intelligence).

Do the life-science "tools" companies actually win from personalized vaccines? The reflex trade was to buy tools stocks on vaccine day, but Holz pushed back: "I'm not so sure… I think this is the AI capability in the life science space [that wins]. I feel like that might have been overly [rewarded] today" (CNBC's "Fast Money").

Does the vaccine change Merck's Keytruda patent cliff? Consensus was no: Holz noted Merck has "done… five deals over the past few years that get them most of the way through," so the new product "takes the pressure off" and gives more deal-making "ammunition" rather than solving the cliff (CNBC's "Fast Money"). A guest on Squawk on the Street went further, arguing Merck is undervalued because the market hasn't priced in that management has already filled the Keytruda gap.

How low can GLP-1 prices really go? The $40–$50/month scenario is optimistic and competition-driven, but the same episode flags the counter-risk: someone still has to manufacture the peptide, and today that "someone" is largely China (WuXi), so supply security, not just price, is the swing factor (On The Pen GLP-1 News).

AI drug discovery, real acceleration or narrative? Optimists cite Insilico's 18-month timeline and Ginkgo's automation numbers; realists on the same shows insist the honest win is fewer late-stage failures via better screening, and warn that biased training data and the preclinical-to-clinical translation gap remain unsolved (Chat GPT Podcast; The Big Unlock).

Drug pricing politics. On Pivot, Mark Cuban made the case that the real cost lever is middlemen (pharmacy benefit managers) and market structure rather than the drugmakers alone, tying into the broader IRA/biosimilars debate.

3. Stock-by-Stock: Bull vs. Bear (as argued by guests)

Moderna (MRNA). Bull: mRNA validated beyond COVID; a personalized cancer-vaccine platform with nine more tumor programs; huge short interest (50M shares) that can keep fueling upside. Bear: Daily Stock Picks called it "binary outcome speculation, not an investment," trading at ~$120 on 17.6x sales with "no analyst above $77," and noted Moderna holds only about $3 billion in cash versus BioNTech's ~$15 billion (Telltales). Verdict from that host: "trade it, don't own it."

Merck (MRK). Bull: record high on the vaccine news, described as "the defensible long-term investment of the two," with growing revenue, a 73% gross margin and a 2.36% dividend (Daily Stock Picks); one guest argued it's outright undervalued because the Keytruda cliff is already being filled (Squawk on the Street). Bear: the vaccine doesn't erase the Keytruda cliff; it just buys time and more M&A firepower (CNBC's "Fast Money").

Eli Lilly (LLY). Bull: Q2 revenue $23B up 48%, an 11% beat, raised full-year EPS guidance to $35.50–$36.50, first UK approval for its oral GLP-1 pill, dominant tirzepatide franchise ($9.94B Mounjaro + $4.93B Zepbound), and no near-term patent cliff, which is "why the stock has been parabolic" (Telltales; DHUnplugged; CNBC's "Fast Money"). Bear: the coming price collapse toward $40–$50/month and a flood of new GLP-1 entrants (On The Pen GLP-1 News).

Novo Nordisk (NVO). Bull: its oral semaglutide pill is a future growth driver, and Novo pioneered the underlying GLP-1 chemistry (DHUnplugged; Healthy Dialogue). Bear: still trailing Lilly on the market's key drugs and exposed to the same price-war and China-supply risks.

BioNTech (BNTX). Bull: flagged as the cheaper way to play cancer vaccines, "incredibly cheap on almost every metric," with its own bladder-cancer and other tumor trials and a much larger ~$15B cash pile (CNBC's "Fast Money"; Telltales). Bear: its competing readouts are on an undetermined timeline.

J&J (JNJ), Gilead (GILD), Biogen (BIIB), Amgen (AMGN): grouped as winners riding oncology and immunology pipelines to all-time or near-all-time highs; J&J specifically praised for having already navigated "the worst of" its patent cliff, clearing "the coast… for the next four or five years" (CNBC's "Fast Money"; Daily Stock Picks).

argenx. Bull: Vyvgart heading past $6B in sales, profitable, and now buying Forte Biosciences ($2.2B) to add potential blockbusters in celiac disease and vitiligo, the poster child for the mid-cap-buyer trend (Citeline Podcasts). Bear: unproven as an acquirer/integrator: "we still haven't seen how they're going to operate as acquirers."

Celcuity (CELC): profiled as a first-approval story: FDA approval on July 14, 2026 for gedatolisib (brand RevTorpic) with fulvestrant in a HR-positive/HER2-negative, non-PIK3CA breast-cancer subset (~37,000 U.S. women/year), with two Phase 3 first-line trials targeting a ~90,000-patient opportunity (Business Of Biotech).

CRISPR Therapeutics (CRSP) / Vertex (VRTX): their gene-editing sickle-cell therapy Casgevy generated $76 million in Q2 2026 revenue (up 78% quarter-on-quarter, 151% year-on-year) under a 60/40 Vertex-CRISPR split, but CRISPR still posted a $90 million net loss and continues to burn cash (Brew Markets).

Medtech quick hits (DeviceTalks): J&J won FDA clearance for its Monarch Quest 3 robotic-bronchoscopy software, a week after Noah Medical's Galaxy 2 and following Intuitive Surgical's system-wide AI upgrade for its Ion platform; software is becoming the competitive battleground. Medtronic faces a $382 million antitrust jury verdict owed to Applied Medical. Haemonetics reconnected with CSL on a plasma-collection supply deal analysts peg at $183–$223 million/year. And activist Sessa Capital took a 9.9% stake in continuous-glucose-monitor maker Senseonics, whose Q2 revenue more than doubled to $14.5 million.

4. Notable Quotes

  • "If you could train your immune cells to be like hunting dogs, chasing the tumor and you could unleash them… that's what this result does." Dr. Dean Li, head of Merck Research Laboratories, on the cancer vaccine (Squawk Pod).
  • "You will get a different drug if you're diagnosed with melanoma today and I'm diagnosed by the same doc… we aim to improve an algorithm to pick 34 mutations that we believe are the most important in your tumor." Stephane Bancel, CEO of Moderna (Squawk Pod).
  • "We do not use your own cells to make the product… It's enzymes. It's a chemical process." Bancel, on why this vaccine should be cheaper and faster to manufacture than CAR-T (Squawk Pod).
  • "50 million shares short to begin the day. You knew this was going to happen. The magnitude, I think, surprised everyone." Jared Holz, Mizuho, on the Moderna squeeze (CNBC's "Fast Money").
  • "Merck is the defensible long-term investment of the two… 73% gross margin, 2.36% dividend. Moderna is the binary outcome speculation, not an investment… 17.6 times sales, no analyst above $77." Host of Daily Stock Picks.
  • On WuXi AppTech and GLP-1 supply: regulators and industry observers are saying "this company is too big to ban… we're relying really heavily on [it] for pharmaceuticals… and especially GLP-1s." Dave Knapp (On The Pen GLP-1 News).
  • On the FDA nominee: her involvement in the childhood-vaccine executive order was "almost disqualifying," per Republican Senate Health Chair Bill Cassidy, as relayed on Citeline Podcasts' Drug Fix.

5. Catalysts to Watch

  • Full Moderna/Merck melanoma data at a major oncology meeting this fall, plus a peer-reviewed journal publication and regulatory discussions "in the next few months" (Squawk Pod). Possible approval by 2027 (Limitless: An AI Podcast).
  • Moderna/Merck cancer-vaccine data in other tumor types (lung, bladder, kidney, stomach, pancreas) expected in 2027; BioNTech bladder-cancer readouts on an undetermined timeline (CNBC's "Fast Money").
  • daraxonrasib (oral KRAS inhibitor): expected FDA approval "within months," a potential inflection for pancreatic and other KRAS-driven cancers (OncLive On Air).
  • Heidi Overton's FDA confirmation hearing: expect a bipartisan grilling on vaccines and a partisan one on the abortion pill; timing uncertain given the Senate recess and midterms (Citeline Podcasts' Drug Fix).
  • More mid-cap M&A: guests expect the dealmaking pace (argenx, Jazz, Insmed, Neurocrine, etc.) to continue, with Merck and others "plenty more active" through year-end and chatter about an AstraZeneca–Bristol Myers tie-up (Citeline Podcasts; Squawk on the Street).
  • Moderna pipeline milestones: rare-disease Phase 3 data expected by year-end and a new push into autoimmune disease (Squawk Pod).
  • Regulatory reform for individualized genetic medicines: the "One to Millions" initiative aims to shift the FDA from product-based to process-based approval for one-off gene therapies (The BioCentury Show).